The device is designed to enhance the administration of subcutaneous therapeutics for diabetics. Credit: Steve Buissinne from Pixabay.

NuGen Medical Devices has entered a five-year distribution agreement with Verrue Consulting Group for its needle-free InsuJet device in Belgium.

InsuJet is designed to enhance the administration of subcutaneous therapeutics for diabetics, aiming to improve care delivery and patient quality of life. It has received approval for sale in Belgium as a medical device.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Effective 17 December 2023, Verrue became an official distributor for the InsuJet device of NuGen.

NuGen expects the partnership to generate sales of $2.4m if the 7,300-device target is met during the agreement period.

The company anticipates a gross margin of 72% from this deal.

See Also:

The distribution channels will include clinics, online platforms, pharmacies and local sales agents. InsuJet device sales training was completed last month by Verrue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NuGen CCO Karen Dunlap said: “I am pleased to introduce Verrue who will be a distributor for the InsuJet needle-free injector in Belgium.

“Their experienced sales team will be introducing InsuJet’s advantages, features, and benefits for patients partnering with self-employed nurses/diabetes educators offering training and sales along with post-sales support.”

Verrue has identified a potential market of 770,000 patients with type 1 diabetes in Belgium, which will be the initial focus for InsuJet sales.

To support these efforts, Verrue plans to utilise a network of self-employed nurses and diabetes educators. This strategic partnership is expected to significantly impact the diabetic care landscape in Belgium.

Verrue general manager Johan Verrue said: “As a distributor for NuGen in Belgium, we are excited to revolutionise the Belgian diabetes market with InsuJet.

“We have started to make calls and schedule several appointments with our network of over 1,600+ independent nurses in Belgium alone. We are impressed with what we see and the changes we can deliver with the InsuJet to the diabetic market in Belgium.”